Clinical trial NCT06830889: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Official title: A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: HER2-positive Breast Cancer
Keywords: HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy
Lead sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted: 2025-02-17
Enrollment: 1450
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.


Eligibility criteria: Inclusion Criteria:

1. Sign the informed consent form voluntarily and follow the protocol requirements;
2. Women aged ≥18 years and ≤75 years at the time of written informed consent;
3. Expected survival time ≥6 months;
4. Patients with histologically confirmed HER2-positive invasive breast cancer;
5. Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
6. The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
7. Previous neoadjuvant therapy should meet the prescribed treatment conditions;
8. Had received radical mastectomy;
9. Determine hormone receptor (HR) status;
10. The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks;
11. ECOG score 0 or 1;
12. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
13. No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed;
14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective contraception during the entire treatment cycle and for 7 months after the end of treatment.

Exclusion Criteria:

1. A diagnosis of stage IV metastatic breast cancer was made;
2. Bilateral breast cancer;
3. Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS);
4. Evidence of clinically significant residual disease or recurrent or metastatic disease after neoadjuvant therapy and surgery;
5. Other primary malignancies diagnosed within 5 years before the first dose;
6. Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;
7. Subjects are participating in other clinical studies and receiving anti-tumor treatment;
8. Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose \> 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride \> 480 mg/m2;
9. History of severe cardiovascular or cerebrovascular disease within six months before screening;
10. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
11. Poorly controlled hypertension (systolic blood pressure \&gt; 150 mmHg or diastolic blood pressure \&gt; 100 mmHg);
12. Complicated with pulmonary diseases leading to severe impairment of lung function;
13. A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; CTCAE v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis;
14. Human immunodeficiency virus antibody (HIVAb) positive, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection;
15. Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;
16. Were receiving \&gt within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
17. Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1;
18. Known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1;
19. Had a history of autologous or allogeneic stem cell transplantation or organ transplantation;
20. Have a severe neurological or psychiatric illness;
21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
23. Subjects scheduled to receive live vaccine or within 28 days before the first dose;
24. Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.

Primary outcomes:
measure: Invasive Disease-free Survival (IDFS)
timeFrame: Up to approximately 77 months
Secondary outcomes:
measure: Disease-free Survival(DFS)
timeFrame: Up to approximately 77 months
measure: Distant Recurrence-free Interval (DRFI)
timeFrame: Up to approximately 77 months
measure: Overall Survival (OS)
timeFrame: Up to approximately 77 months
measure: Treatment Emergent Adverse Event (TEAE)
timeFrame: Up to approximately 77 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Jiangsu Province Hospital
state: Jiangsu
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
References: